Evidence map›Paper›PMID 36826062›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Five-Fraction Stereotactic Radiotherapy for Brain Metastases-A Retrospective Analysis.

Julian P Layer, Katharina Layer, Gustavo R Sarria, Fred Röhner, Cas S Dejonckheere, Lea L Friker, Thomas Zeyen, David Koch, Davide Scafa, Christina Leitzen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Julian P LayerDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0001-7692-7775
Katharina LayerDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Gustavo R SarriaDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-5929-7270
Fred RöhnerDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Cas S DejonckheereDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0003-4527-4024
Lea L FrikerInstitute of Experimental Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Thomas ZeyenDivision of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, 53127 Bonn, Germany.
David KochDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Davide ScafaDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-5105-8697
Christina LeitzenDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0001-7397-8569
Mümtaz KöksalDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-8210-0894
Frederic Carsten SchmeelDepartment of Neuroradiology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0003-0985-1517
Niklas SchäferDivision of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, 53127 Bonn, Germany.
Jennifer LandsbergDepartment of Dermatology, University Hospital Bonn, 53127 Bonn, Germany.
Michael HölzelInstitute of Experimental Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Ulrich HerrlingerDivision of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, 53127 Bonn, Germany.
Matthias SchneiderDepartment of Neurosurgery, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-6025-7479
Frank A GiordanoDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Leonard Christopher SchmeelDepartment of Radiation Oncology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.ORCID 0000-0002-3901-4122

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine the safety and outcome profile of five-fraction stereotactic radiotherapy (FSRT) for brain metastases (BM), either as a definitive or adjuvant treatment.

methodsWe assessed clinical data of patients receiving five fractions of 7 Gy each (cumulative physical dose of 35 Gy) to BM or surgical cavities. The primary endpoints were toxicity and radiation necrosis (RN) rates. Secondary endpoints were 1-year cumulative local control rate (LCR) and estimated overall survival (OS).

resultsA total of 36 eligible patients receiving FSRT to a total of 49 targets were identified and included. The median follow up was 9 (1.1-56.2) months. The median age was 64.5 (34-92) years, the median ECOG score was 1, and the median Diagnostic-Specific Graded Prognostic Assessment (DS-GPA) score was 2. Treatment was well tolerated and there were no grade 3 adverse events or higher. The overall RN rate was 14.3% and the median time to RN was 12.9 (1.8-23.8) months. RN occurrence was associated with immunotherapy, young age (≤45 years), and large PTV. The cumulative 1-year local control rate was 83.1% and the estimated median local progression free-survival was 18.8 months. The estimated median overall survival was 11 (1.1-56.2) months and significantly superior in those patients presenting with RN.

conclusionsFSRT with 5 × 7 Gy represents a feasible, safe, and efficient fast track approach of intensified FSRT with acceptable LC and comparable RN rates for both the adjuvant and definitive RT settings.

Indexed as

Brain NeoplasmsDose Fractionation, RadiationFollow-Up StudiesHumansMiddle AgedProgression-Free SurvivalRetrospective Studiesbrain metastasesFSRThypofractionationradiation necrosisstereotactic radiotherapytoxicity

Identifiers

PMID36826062
PMCPMC9955428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.